Open AccessTumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Author(s) -
Lauren P. Levine,
Kelly Mahuron,
Katy K. Tsai,
Clinton Wu,
Daiva M. Mattis,
Mariela Pauli,
Arielle Oglesby,
James C. Lee,
Matthew H. Spitzer,
Matthew F. Krummel,
Alain P. Algazi,
Michael D. Rosenblum,
Michael Alvarado,
Adil Daud
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-08648-7
Subject(s) - medicine , common terminology criteria for adverse events , melanoma , oncology , immunotherapy , adverse effect , neoadjuvant therapy , pneumonitis , surgical oncology , immune checkpoint , ctla 4 , response evaluation criteria in solid tumors , ipilimumab , blockade , immune system , cancer , progressive disease , immunology , t cell , chemotherapy , cancer research , lung , receptor , breast cancer
The frequency of "exhausted" or checkpoint-positive (PD-1 + CTLA-4 + ) cytotoxic lymphocytes (Tex) in the tumor microenvironment is associated with response to anti-PD-1 therapy in metastatic melanoma. The current study determined whether pretreatment Tex cells in locally advanced melanoma predicted response to neoadjuvant anti-PD-1 blockade.